Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ularitide in Acute Decompensated Heart Failure
NCT01661634Phase 3Completed
- Sponsor
- Cardiorentis AG
- Start
- Jul 2012
- Primary completion
- Nov 2015
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 22
01
Overview
Phase 3, randomised, double-blind trial in heart failure (HF) comparing Ularitide with Placebo (2 arms). Primary endpoints: Hierarchical Clinical Composite Variable at 48 hours and Freedom from Cardiovascular Mortality. Started Jul 2012; status: completed.
02
Drugs
ularitide
03
Conditions
heart failure (HF)
Beyond the preview
Go deeper on NCT01661634.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01661634.